Bristol-Myers Squibb Company(BMY-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low54.96
Day High55.67
Open:55.39
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
3 Reasons to Buy Bristol Myers Squibb Stock
StockStory
1 S&P 500 Stock with Solid Fundamentals and 2 We Avoid
DAL
Tipranks
Real-World Data on Nivolumab Plus Chemo in Japanese Gastric Cancer: What Investors Should Watch
Motley Fool
Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook
Tipranks
Bristol-Myers Squibb’s Real World Kidney Cancer Study Signals Durable Immunotherapy Momentum
Motley Fool
3 Dividend Stocks to Hold for the Long Haul
Motley Fool
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.
Tipranks
Bristol-Myers Squibb’s Mavacamten Study Signals Real‑World Momentum in Heart Drug Market
Tipranks
Bristol-Myers Squibb Advances Phase 1 Liver Study for New Drug BMS-986435
Zacks Investment Research
Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines?
Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines?
Motley Fool
Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.
Tipranks
Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
Zacks Investment Research
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
Motley Fool
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?
Tipranks
Analysts Are Bullish on These Healthcare Stocks: ADC Therapeutics (ADCT), Bristol-Myers Squibb (BMY)
Tipranks
Analysts Offer Insights on Healthcare Companies: Novartis (NVS), Amgen (AMGN) and Bristol-Myers Squibb (BMY)
Motley Fool
Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
Motley Fool
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?
StockStory
3 Value Stocks We Think Twice About
ICFI

Profile

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.